arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Merck & Company, Inc.

MRK Health Care Biotechnology: Pharmaceutical Preparations
$150.33
▲ +0.0% Today
as of Sep 4, 16:51 ET
Last 30 days +14.97% Jul 27 → Sep 04
$125.48 $133.79 $142.11 $150.43 $158.74 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$150.83
High
$152.22
Low
$150.09
Volume
$4M
Avg Vol
$12M
Mkt Cap
$317.1B
P/E (TTM)
—
Beta
—
52w High
$156.92
52w Low
$77.58
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 0 ● 25 ▼ 0
Sep 4 · 21:45 Zacks neutral
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Sep 4 · 17:09 Simply Wall St. neutral
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
Sep 4 · 09:31 MT Newswires neutral
Wells Fargo Adjusts Price Target on Merck & Co. to $170 From $150, Keeps Overweight Rating
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$78
$157
92% of range
Avg surprise (last 2)
+4.6%
Avg reaction (last 1)
+1.4%
100% positive
Latest IV / EM
32%
EM ±1.3% · $153 · Sep 4

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.35$-1.18$-0.02$1.15$2.32 Actual $1.11Actual $-2.35Actual $1.86Actual $1.87Actual $2.14Actual $1.24Actual $2.22Est $2.15Actual $2.13Est $2.01Actual $2.32Actual $-1.72Actual $-0.54 MarJunSepMarJunSepMar/2025Jun/2025SepMarJun
Revenue vs Net Income Revenue Net income
$-4.2B$1.4B$6.9B$12.5B$18.1B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.54 — — — — financials
Tue Mar 31, 2026Mar 2026 $-1.72 — — — — financials
Tue Sep 30, 2025Sep 2025 $2.32 — — — — financials
Tue Jul 29, 2025Jun/2025 $2.13 $2.01 +6.0% — — earnings
Thu Apr 24, 2025Mar/2025 $2.22 $2.15 +3.3% — +1.4% earnings
Mon Sep 30, 2024Sep 2024 $1.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $2.14 — — — — financials
Sun Mar 31, 2024Mar 2024 $1.87 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.86 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.35 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.11 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$16.61B$16.29B—$17.28B$15.81B$15.53B—$16.66B
Cost of revenue$4.39B$4.20B—$3.85B$3.56B$3.42B—$4.08B
Gross profit————————
Operating income————————
Net income$-1.33B$-4.24B—$5.79B$4.43B$5.08B—$3.16B
EPS (diluted)$-0.54$-1.72—$2.32$1.76$2.01—$1.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$6.85B$5.33B$14.56B$18.17B$8.01B$8.63B$13.24B$14.59B
Inventory$6.21B$6.48B$6.66B$6.44B$6.60B$6.20B$6.11B$6.24B
Total current assets$36.68B$35.02B$43.52B$47.56B$37.06B$35.50B$38.78B$40.36B
Total assets$129.80B$128.69B$136.87B$129.55B$117.52B$115.12B$117.11B$117.53B
Long-term debt$51.08B$46.67B$46.75B$39.97B$33.97B$33.48B$34.46B$34.98B
Total liabilities————————
Total equity$41.93B$45.93B$52.61B$51.85B$49.06B$48.40B$46.31B$44.56B

Implied volatility — last 90 days

25%204%383%562%741% Jun 07 — IV 34% · EM ±3.2%Jun 08 — IV 34% · EM ±2.9%Jun 09 — IV 36% · EM ±2.6%Jun 10 — IV 36% · EM ±2.1%Jun 11 — IV 32% · EM ±1.3%Jun 15 — IV 37% · EM ±2.7%Jun 16 — IV 37% · EM ±2.2%Jun 17 — IV 36% · EM ±1.5%Jun 19 — IV 30% · EM ±3.3%Jun 22 — IV 33% · EM ±2.8%Jun 23 — IV 35% · EM ±2.6%Jun 24 — IV 32% · EM ±1.9%Jun 25 — IV 33% · EM ±1.4%Jun 29 — IV 26% · EM ±6.0%Jun 30 — IV 26% · EM ±6.1%Jul 01 — IV 39% · EM ±1.6%Jul 03 — IV 28% · EM ±3.1%Jul 06 — IV 32% · EM ±2.7%Jul 07 — IV 33% · EM ±2.4%Jul 08 — IV 33% · EM ±2.0%Jul 09 — IV 35% · EM ±1.5%Jul 13 — IV 31% · EM ±2.6%Jul 14 — IV 37% · EM ±2.7%Jul 15 — IV 35% · EM ±2.0%Jul 16 — IV 33% · EM ±1.4%Jul 20 — IV 31% · EM ±2.6%Jul 21 — IV 30% · EM ±2.2%Jul 22 — IV 32% · EM ±1.9%Jul 23 — IV 31% · EM ±1.3%Jul 27 — IV 32% · EM ±2.7%Jul 28 — IV 31% · EM ±2.3%Jul 29 — IV 38% · EM ±2.2%Jul 30 — IV 36% · EM ±1.5%Aug 03 — IV 58% · EM ±4.8%Aug 04 — IV 40% · EM ±2.9%Aug 05 — IV 40% · EM ±2.4%Aug 06 — IV 37% · EM ±1.6%Aug 10 — IV 29% · EM ±2.5%Aug 11 — IV 29% · EM ±2.1%Aug 12 — IV 26% · EM ±1.6%Aug 13 — IV 35% · EM ±1.5%Aug 17 — IV 29% · EM ±2.4%Aug 18 — IV 29% · EM ±2.1%Aug 19 — IV 57% · EM ±3.4%Aug 20 — IV 37% · EM ±1.5%Aug 24 — IV 37% · EM ±3.1%Aug 25 — IV 36% · EM ±2.6%Aug 26 — IV 30% · EM ±1.8%Aug 27 — IV 741% · EM ±31.0%Aug 31 — IV 30% · EM ±2.5%Sep 01 — IV 32% · EM ±2.3%Sep 02 — IV 28% · EM ±1.7%Sep 03 — IV 32% · EM ±1.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
AZN
AstraZeneca PLC
$247.5B $161.47-0.8%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in